Literature DB >> 20165744

Treatment of infrabony defects with or without enamel matrix proteins: a 24-month follow-up randomized pilot study.

Daniella Chambrone1, Ivan Munhoz Pasin, Leandro Chambrone, Claudio Mendes Pannuti, Marina Clemente Conde, Luiz A Lima.   

Abstract

OBJECTIVE: To evaluate a comparison of open-flap debridement (OFD) with or without the use of enamel matrix proteins (EMP) for the treatment of infrabony defects. METHOD AND MATERIALS: Ten volunteers (38 infrabony defects) were randomized to receive OFD+EMP (test site) and OFD (control site). Clinical outcomes included mean changes in Plaque Index, Gingival Index, probing pocket depth (PPD), relative attachment level (RAL), gingival recession, width of keratinized tissue, and dental mobility at baseline and at 24 months.
RESULTS: A significant reduction of 4.21+/-0.97 mm was observed in PPD for the OFD+EMP group (from 6.30+/-0.99 mm to 2.09+/-0.97 mm) and of 3.28+/-1.23 mm for the OFD group (from 6.13+/-0.88 mm to 2.85+/-1.42 mm) (P<.001). The reduction in PPD was statistically significantly greater for OFD+EMP compared to OFD (P=.03). The mean RAL decreased from 13.26+/-1.88 mm to 7.57+/-2.05 mm for the OFD+EMP group (a gain of 5.69+/-1.96 mm) and from 13.37+/-1.71 mm to 8.13+/-1.34 mm (P<.001) for the OFD group (a gain of 5.24+/-1.55 mm). Gingival recession was higher in the OFD+EMP group than in the OFD group. The mean keratinized tissue significantly decreased from 4.41+/-1.39 mm to 3.63+/-1.54 mm for OFD flap group (P<.01).
CONCLUSION: Both treatment modalities were efficient in improving RAL and PPD. Within groups, there was a significant reduction in keratinized tissue for OFD and a significant postoperative recession for the OFD + EMP group. Infrabony defects treated with OFD + EMP showed significantly more PPD reduction when compared to OFD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20165744

Source DB:  PubMed          Journal:  Quintessence Int        ISSN: 0033-6572            Impact factor:   1.677


  2 in total

1.  Gene array of primary human osteoblasts exposed to enamel matrix derivative in combination with a natural bone mineral.

Authors:  Richard J Miron; Dieter D Bosshardt; Yufeng Zhang; Daniel Buser; Anton Sculean
Journal:  Clin Oral Investig       Date:  2012-05-03       Impact factor: 3.573

2.  Two-year randomized clinical trial of enamel matrix derivative treated infrabony defects: radiographic analysis.

Authors:  Mariana Schutzer Ragghianti Zangrando; Daniela Chambrone; Ivan Munhoz Pasin; Marina Clemente Conde; Cláudio Mendes Pannuti; Luiz Antônio Pugliesi Alves de Lima
Journal:  BMC Oral Health       Date:  2014-12-04       Impact factor: 2.757

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.